Chinmay Jani, MD, highlights non-smoking risk factors, the impact of lung cancer on younger populations, and the value of comprehensive molecular testing.
|Videos|August 10, 2017
Surgical Management of Stage III (N2) Lung Cancer
Author(s)Linda Martin, MD, MPH
This video reviews the role of surgery in patients with stage III (N2) non–small-cell lung cancer, highlighting some of the challenges in studying these patients and the need for multidisciplinary patient evaluations.
Advertisement
In this video, Linda Martin, MD, MPH, of the University of Virginia Health System in Charlottesville, reviews the role of surgery in patients with stage III (N2) non–small-cell lung cancer, highlighting some of the challenges in studying these patients and the need for multidisciplinary patient evaluations to best determine appropriate treatment strategies.
Martin gave a presentation on this topic earlier this year at the 2017 Multidisciplinary Thoracic Cancers Symposium.
Advertisement
Related to this article
Dwight H. Owen, MBBCh, MS, discussed why severe immune-related toxicities remain hard to predict as immunotherapy combinations expand in lung cancer.
Presentations at ESMO Congress 2026 detailed how surgery, radiation oncology, and supportive care can contribute to the treatment of patients with NSCLC.
"As we combine more treatments…they have overlapping toxicities, and they may have the ability to synergize in a negative way," said Dwight H. Owen, MBBCh, MS.
Advertisement
Advertisement
Trending on CancerNetwork
1
AI-Measured Tumor Volume on PSMA PET-CT Linked With Survival in Prostate Cancer
2
Mapping Practical Steps to Expand CAR T-Cell Access in Multiple Myeloma
3
Scaling Low-Dose Radiation Therapy for Osteoarthritis Across a Network
4
Surgery Correlates With Better Survival Vs SABR in Early-Stage NSCLC
5